Qiagen N.v. · NYSE:QGEN
Qiagen — Jefferies 2021 Healthcare Conference
100 slides from Qiagen's conference presentation, Dec 6, 2021
Slide 1: Investor Handout
Investor Handout QIAGEN: A stronger company set for solid post-pandemic growth Q4 2021 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.
Slide 3: Table of Contents
Table of Contents About QIAGEN 4 Sustainability 51 • QIAGEN at a glance 4 • Environmental 54 • Global presence 6 • Social 57 • Customers 7 • Governance / Leadership 61 • Sales and EPS performance 10 • Strategy 11 Q3 2021 Results 69 Product portfolios 15 • Sample technologies 17 • Diagnostic solution
Slide 4: QIAGEN at a glance
QIAGEN at a glance 2020 sales Global sales reach $1.8 bn 44% Americas 48% 52% 37% EMEA 19% Asia-Pacific / Japan Molecular Life Diagnostics Sciences >6,000 employees ~85% ~15% Innovative cutting-edge portfolios worldwide Highly recurring consumables Instruments and related revenues • World leader in
Slide 5: Comprehensive portfolio to help customers unlock valuable molecular insights
Comprehensive portfolio to help customers unlock valuable molecular insights Sample technologies Assay technologies Advancing understanding of life Faster and better drug R&D Better diagnoses Sample to Insight solutions Ensuring public safety Automation systems Bioinformatics VALUABLE BIOLOGICAL MOL
Slide 6: Our global presence: Focused on the most attractive developed and emerging markets
Our global presence: Focused on the most attractive developed and emerging markets Sollentuna Venlo Aarhus Distribution Manchester Wroclaw Toronto Beverly Hilden partners Paris Milan Seoul Barcelona Ankara Beijing Tokyo in >60 Redwood City Germantown / Cairo New Delhi countries Shanghai Frederick Du
Slide 7: Our customers: Addressing the world’s most pressing challenges
Our customers: Addressing the world’s most pressing challenges >500,000 customers benefiting from the value of molecular insights Life Sciences Academia How can we achieve scientific breakthroughs even faster? Pharma How can we develop better and safer drugs? Applied Testing How can we improve publi
Slide 8: Life Sciences: Enabling the advancement of science with differentiated technologies
Life Sciences: Enabling the advancement of science with differentiated technologies Academia ~$5 billion QIAGEN value addressable market • 2020 sales of ~$966 million ~5-6% CER • Recognized innovator supporting breakthrough science Pharma market growth • Ability to translate innovations into commerc
Slide 9: Molecular Diagnostics: Improving outcomes for patients and increasing lab efficiencies
Molecular Diagnostics: Improving outcomes for patients and increasing lab efficiencies ~$6 billion addressable QIAGEN value market • 2020 sales of ~$904 million • Focused on high-growth, high-demand opportunities Molecular ~6-7% CER Diagnostics market growth(1) • Strong automation portfolio expansio
Slide 10: Strong foundation for double-digit CER sales growth from non-COVID products
Strong foundation for double-digit CER sales growth from non-COVID products Annual sales trends Adjusted diluted EPS trends In $ per share (CER) ≥15% CER(1) ≥ $2.48 CER(1) $1.8 bn $2.17 $1.5 bn $1.5 bn $1.4 bn $1.3 bn $1.43 $1.34 $1.27 $1.11 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 202
Slide 11: Our strategy: Unwavering focus on five pillars of growth
Our strategy: Unwavering focus on five pillars of growth 2019: 2020 and beyond: Pursuing a broad range of opportunities Sharpened focus on five pillars of growth Portfolio with multiple new launches – but diluted efforts Ability to take top 3 leadership position with waves of organic growth Sample Q
Slide 12: Differentiated core business provides anchor to develop five pillars of growth
Differentiated core business provides anchor to develop five pillars of growth Five pillars of growth Sample QIAcuity QIAstat-Dx NeuMoDx QuantiFERON technologies Pillars of growth supported by core business Core business Genomics / NGS Precision PCR / Nucleic acid Human ID / QIAGEN OEM Medicine ampl
Slide 13: Five pillars targeting >$6 billion opportunities of our $11 billion total addressable market
Five pillars targeting >$6 billion opportunities of our $11 billion total addressable market Sample technologies QIAcuity QIAstat-Dx NeuMoDx QuantiFERON Strengthen excellence in Enter digital PCR Accelerate Fully integrate Extend leadership in Sample technologies market with QIAcuity QIAstat-Dx adop
Slide 14: Investing to drive further waves of growth in five pillars
Investing to drive further waves of growth in five pillars Executing on a roadmap to fuel robust growth beyond 2021 Q3 2021 status 2021 plan 2022 plan 2023 and beyond Sample Broadest portfolio with • New automation workflows • New applications • Next generation platforms technologies leading brand r
Slide 15: Five pillars update: Investing to drive solid post-pandemic business expansion
Five pillars update: Investing to drive solid post-pandemic business expansion 2021 CER sales expectations Post-COVID dynamics Sample technologies >$750 m • Sustainable low- to mid-single-digit CER growth QIAcuity >$45 m • Sustainable double-digit CER growth digital PCR QIAstat-Dx >$60 m • Sustainab
Slide 16: QIAGEN product portfolios
QIAGEN product portfolios Sample to Insight
Slide 17: Reporting sales in product groups
Reporting sales in product groups Five pillars of growth Sample QIAcuity QIAstat-Dx NeuMoDx QuantiFERON QIAGEN product groups technologies(1) digital PCR(3) Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control includin
Slide 18: Sample technologies
Sample collection, stabilization Manual sample preparation and storage solutions Sample technologies Customers Automated sample preparation Quality control instruments Life Sciences Molecular Diagnostics Sample to Insight Investor handout – Q4 2021 18
Slide 19: The first step in virtually any molecular biology laboratory process
Sample technologies The first step in virtually any molecular biology laboratory process QIAGEN holds leading products in the vast majority of applications mRNA microRNA Gel extraction Total RNA from FFPE tissue Post-reaction cleanup Total RNA from whole blood (i.e. PCR, enzyme digestion) ~70-75% of
Slide 20: The solid foundation of the QIAGEN story
Sample technologies The solid foundation of the QIAGEN story From a strong start with plasmid kits to a market leading portfolio for sample collection, stabilization and purification QIAGEN pioneered the nucleic All kits based on acid purification kit – Spin-column purification the same easy-to- rev
Slide 21: Offering a full range of hands-free sample preparation automation
Sample technologies Offering a full range of hands-free sample preparation automation Advanced platforms to automate QIAGEN sample technologies for low to high sample volumes QIAcube Connect QIAcube HT EZ1 / EZ2 QIAsymphony Automation option for QIAGEN 96-well plate format using the Automation with
Slide 22: SPOTLIGHT: QIAsymphony – Flagship platform for sample processing
Sample technologies SPOTLIGHT: QIAsymphony – Flagship platform for sample processing Off-the-shelf solutions and customizable protocols to fit wide range of laboratory needs • Over 400 new placements in 2020 • Front-end automation solution for molecular testing • Regionalization strategy ◦ US: Focus
Slide 23: Diagnostic solutions
Immune Response Infectious diseases Diagnostic solutions Oncology and Precision Medicine Women’s Health Customers Molecular Diagnostics Sample to Insight Investor handout – Q4 2021 23
Slide 24: Immune Response: Best-in-class IGRA test for latent tuberculosis
Diagnostic solutions Immune Response: Best-in-class IGRA test for latent tuburculosis What is QuantiFERON? QuantiFERON-TB Gold Plus (QFT-Plus) is a simple blood test that aids in the detection of Mycobacterium tuberculosis, the bacteria which causes tuberculosis (TB). Latent TB testing market QFT-Pl
Slide 25: A growing market demand for modern latent TB testing
Diagnostic solutions A growing market demand for modern latent TB testing What is the difference between latent TB and active TB? Latent TB infection (LTBI) can persist for weeks, months or years before ~70 million latent TB tests per year across the world developing into active disease. Although LT
Slide 26: QuantiFERON offers fully automated workflows for low and high throughput testing
Diagnostic solutions QuantiFERON offers fully automated workflows for low and high throughput testing Enabling hands-free processing of QFT-TB Gold Plus QuantiFERON differentiation Strong best-in-class market position DiaSorin Full automation capability • High performing assay: QFT TB Gold Plus (4th
Slide 27: QuantiFERON Lyme: Combination of tests allowing a new level of detection
Diagnostic solutions QuantiFERON Lyme: Combination of tests allowing a new level of detection CE-IVD test launched April 2021 Rising occurrence of Lyme disease Confirmed cases Potential testing market 40,000 Europe ~35,000 per year ~12-14 million tests per year U.S. ~30,000 per year ~5 million tests
Slide 28: Infectious diseases: New generation of PCR technology for urgent needs
Diagnostic solutions Infectious diseases: New generation of PCR technology for urgent needs Core / Hospital laboratories Near-patient clinical laboratories Hospital and Community hospitals and reference lab networks reference lab “outreach” centers Requirements: Requirements: Market opportunity Mark
Slide 29: QIAstat-Dx: Capturing opportunities in the rapidly growing market of syndromic testing
Diagnostic solutions QIAstat-Dx: Capturing opportunities in the rapidly growing market of syndromic testing What is syndromic testing? Syndromic testing is a new approach to molecular diagnostic testing which uses a single test to look for multiple viral, bacterial or fungal infections. Sets of comm
Slide 30: QIAstat-Dx: Reliable, fast and cost-effective diagnosis of complex syndromes
Diagnostic solutions QIAstat-Dx: Reliable, fast and cost-effective diagnosis of complex syndromes Unrivaled ease-of-use – no sample preparation required Liquid / solid sample input Dry swab sample input Self- contained cartridge Real-time PCR reaction chambers Analytical modules Operational module •
Slide 31: QIAstat-Dx: Accelerated commercialization setting-up post-pandemic growth opportunities
Diagnostic solutions QIAstat-Dx: Accelerated commercialization setting-up post-pandemic growth opportunities Menu expansion plans 2021 and beyond ambitions Completed CE-IVD • 2021 sales target: >$60 million THOMAS U.S. Submissions planned and completed NEW DESIGN FROM Gastrointestinal • Create broad
Slide 32: QIAstat-Dx: Novel syndromic testing system delivering unique value
Diagnostic solutions QIAstat-Dx: Novel syndromic testing system delivering unique value QIAstat-Dx Biofire FilmArray Biofire Torch Luminex ePlex Genmark Verigene (4 scalable slots (1 slot) (12 slots) (12 slots) (1 slot) Competitive benchmarking used for comparison) Throughput (in 8 hours) 28 9 108 6
Slide 33: NeuMoDx: Bringing simplicity of clinical chemistry to integrated PCR testing
Diagnostic solutions NeuMoDx: Bringing simplicity of clinical chemistry to integrated PCR testing New generation of integrated PCR NeuMoDx differentiation • Two scalable platforms: 96 and 288 • Easier: Three-step workflow process • Fully acquired in September 2020 • Faster: First results in ~1 hour
Slide 34: NeuMoDx: Robust start on installed base build-out and accelerated menu expansion
Diagnostic solutions NeuMoDx: Robust start on installed base build-out and accelerated menu expansion Menu expansion plans 2021 and beyond ambitions Submissions planned and completed CE-IVD U.S. • 2021 sales target: >$100 million HBV 2022 ◦ Implement agressive menu expansion plans Blood borne viruse
Slide 35: NeuMoDx: A unique integrated PCR testing platform in >$3 billion market opportunity
Diagnostic solutions NeuMoDx: A unique integrated PCR testing platform in >$3 billion market opportunity Competitive benchmarking Roche Cobas Hologic Hologic 6800 Roche Cobas Beckman Veris NeuMoDx 288 NeuMoDx 96 Panther Abott Alinity M Panther (+ Omni LDT 8800 (Discontinued) Fusion channel) Volume i
Slide 36: Oncology and Precision Medicine: QIAGEN as a partner of choice
Diagnostic solutions Oncology and Precision Medicine: QIAGEN as a partner of choice >25 pharma partnerships CDx and LDT Market >$1.1 billion annually >50 active development programs ~15% CAGR Currently mostly LDT’s 7 FDA approvals and 5 CE-IVD to date Day One Lab Readiness program Program designed t
Slide 37: Oncology and Precision Medicine: QIAGEN as a partner of choice
Diagnostic solutions Oncology and Precision Medicine: QIAGEN as a partner of choice QIAGEN molecular diagnostic development Offering both 26 IVD development programs either in pre-clinical or clinical phase PCR and NGS technologies 20 CDx (Pharma sponsored) programs in clinical development for CDx I
Slide 38: Women’s Health: Prenatal testing and detection of sexually transmitted diseases
Diagnostic solutions Women’s Health: Prenatal testing and detection of sexually transmitted diseases Cervical cancer screening • Digene – Comprehensive range of human papillomavirus DNA test Maternal / Fetal testing • AmniSure – For the detection of PAMG-1 in amniotic fluid of pregnant women • Parto
Slide 39: PCR / Nucleic Acid amplification
Digital PCR - QIAcuity PCR reagents and instrumentation PCR / Nucleic Acid amplification Customized arrays Customers Life Sciences Sample to Insight Investor handout – Q4 2021 39
Slide 40: PCR: One of the most widely used tools in molecular biology
PCR / Nucleic acid amplification PCR: One of the most widely used tools in molecular biology What is polymerase chain reaction (PCR)? What is a PCR array? The process of replicating a specific DNA fragment though a series of thermal cycling to generate thousands to millions of copies. A PCR array or
Slide 41: Digital PCR: A new level of precision and sensitivity
PCR / Nucleic acid amplification Digital PCR: A new level of precision and sensitivity What is digital PCR? Digital PCR is a highly accurate approach for nucleic acid detection and quantification. The basic principle is the same as other PCR technologies Replicating a specific DNA fragment though a
Slide 42: Digital PCR: The latest generation of PCR technology
PCR / Nucleic acid amplification Digital PCR: The latest generation of PCR technology 1st generation 2nd generation 3rd generation Conventional PCR Quantitative RT-PCR (qPCR) Digital PCR (dPCR) Qualitative Relative quantification Absolute quantification • Technically simple • High accuracy, sensitiv
Slide 43: QIAcuity: Disruptive nanoplate-based digital PCR system
PCR / Nucleic acid amplification QIAcuity: Disruptive nanoplate-based digital PCR system Workflow advantages with QIAGEN digital PCR using novel microplate technology Fully integrated platforms Differentiated nanoplate system Partitioning, thermal cycling and imaging Launched • Each square well cont
Slide 44: QIAcuity: Capturing opportunities in both dPCR and qPCR markets
PCR / Nucleic acid amplification QIAcuity: Capturing opportunities in both dPCR and qPCR markets Longer-term ambition to convert various PCR markets QIAcuity Market Opportunity • 2021 sales: >$45 m vs. ~$10 million in 2020 ~$300 million annual digital PCR market • Launched COVID-19 research assay in
Slide 45: PCR enzymes, reagents, and arrays for research workflows
PCR / Nucleic acid amplification PCR enzymes, reagents, and arrays for research workflows QuantiNova: Automatable, ultrafast kits with in-process PCR arrays: pathway-focused panels of laboratory- controlled safety measures verified qPCR assays • PCR or 1-step & 2-step RT-PCR • Expert-designed panels
Slide 46: Customized arrays: GeneGlobe design and analysis portal for biological content
PCR / Nucleic acid amplification Customized arrays: GeneGlobe design and analysis portal for biological content A world of genes, pathways and biological targets Find NGS, PCR and functional analysis assays in the relevant scientific context. Design custom products with full flexibility on target re
Slide 47: Genomics / NGS
Universal NGS consumables Illumina collaboration NGS assays Genomics / NGS Customers Bioinformatics solutions Life Sciences Molecular Diagnostics Sample to Insight Investor handout – Q4 2021 47
Slide 48: Universal NGS: QIAseq solutions providing high-performance chemistry
Genomics / NGS Universal NGS: QIAseq solutions providing high-performance chemistry Target enrichment and streamlined library preparation leveraging leading sample preparation and bioinformatics QIAGEN NGS differentiation NGS research market Superior technology performance for target enrichment >$80
Slide 49: Partnership to accelerate use of NGS in clinical decision-making
Diagnostic solutions Partnership to accelerate use of NGS in clinical decision-making • QIAGEN to develop and market NGS IVD kits (including CDx assays) for use on Illumina systems ◦ Integrated with QIAGEN sample technologies, NGS IVD kits and bioinformatics solutions for “Sample to Insight” experie
Slide 50: QIAGEN Digital Insights: Turning sequencing data into clinically actionable information
Genomics / NGS QIAGEN Digital Insights: Turning sequencing data into clinically actionable information Bioinformatics [baɪ.oʊˌɪnfərˈmætɪks] is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformati
Slide 51: The partner of choice for actionable insights from molecular and real-world data
Genomics / NGS The partner of choice for actionable insights from molecular and real-world data Recent multi-year partnerships Preferred vendor for Genomics Deliver custom NGS patient data Molecular oncology and England to analyze 5 million interpretation for genetic markers oncogenetic screening da
Slide 52: Sustainability at QIAGEN
Sustainability at QIAGEN Sample to Insight
Slide 53: We were awarded Prime Status by ISS-ESG
We were awarded Prime Status the sustainability ratings agency, ISS-ESG Awarded to companies with an Environmental, Social and Governance (ESG) performance above the sector-specific prime threshold, which means they fulfill ambitious absolute performance requirements We communicate our activities ar
Slide 54: Dedicated to sustainability and diversity in our operations and teams
Dedicated to sustainability and diversity in our operations and teams Environmental Social Governance 1.5-degree Celsius climate target Community Service Committee Recognizing importance of clear organizing volunteers and funds rules on corporate governance Progress in 2020: • Compliance with rules
Slide 55: Environmental protection is an issue of continued and committed concern for QIAGEN
Environmental protection is an issue of continued and committed concern for QIAGEN Eco-friendly transportation • Conversion of air freight to sea freight saving ~1.164 tons/year of CO₂ since 2018 • Reduction of Scope 1 & 2 CO₂ emissions by 9.1% in 2020 • Reduction of business travel CO₂ emissions by
Slide 56: Integrating sustainability throughout the value chain
Integrating sustainability throughout the value chain Examples of sustainability in product design • Avoiding materials that cause a lot of damage when they are mined, cannot be recycled or do not decompose • Improving repairability, longevity, and allowing for reuse • Designing products to use less
Slide 57: Plastic footprint reduction
Plastic footprint reduction Committed to reduce, replace, and recycle plastic waste without compromising the required safety and hygiene standards Reduce Reduced the thickness of blister film in packaging equating to a 2800 kg annual reduction Reduced the number of gel packs used equating a 33.4 ton
Slide 58: Conducting business in a responsible way through ethical foundations
Conducting business in a responsible way through ethical foundations Respecting human rights and legally compliant business behavior Supply Chain As part of our supplier selection process, we assess the suppliers’ policy regarding human rights issues. In addition, first-tier suppliers must confirm R
Slide 59: Deepening commitment to diversity and inclusion
Deepening commitment to diversity and inclusion Diverse teams strengthen our organization through the variety of ideas, perspectives and approaches Executive Council on Equal Opportunity (ECEO) • Created to drive change within QIAGEN around diversity and inclusion Diversity and Inclusion Ambassador
Slide 60: Fostering a culture of empowerment driven by a focus on achieving targets
Fostering a culture of empowerment driven by a focus on achieving targets Team developed and empowered to execute on our goals Decentralized decision-making Ambitious but realistic targets A culture of “doers” • Giving teams at all levels greater influence • Appropriately balance opportunity and ris
Slide 61: Our employee volunteer committees drive initiatives across the organization
Our employee volunteer committees drive initiatives across the organization Our diversity ambassadors The Mexico “QIAGreen” team regularly organize roundtables and organizes recycling events and workshops to discuss topics environmental education campaigns around inclusion and equality Our teams are
Slide 62: QIAGEN operates under a two-tier corporate structure
QIAGEN operates under a two-tier corporate structure • QIAGEN has established an Executive Committee (EC) – which comprises the CEO, the CFO and certain experienced leaders. • Under leadership of the CEO, the members of the Executive Committee share powers and responsibilities for operational manage
Slide 63: Executive Committee / Managing Board
Executive Committee / Managing Board Thierry Bernard Roland Sackers Chief Executive Officer Chief Financial Officer Joined QIAGEN in February 2015 to lead QIAGEN’s growing Joined QIAGEN in 1999 as Vice President Finance and has presence in Molecular Diagnostics, the application of Sample been Chief
Slide 64: Executive Committee
Executive Committee Dr. Thomas Schweins Jean-Pascal Viola Dr. Jonathan Sheldon Sr. Vice President, Head of Life Science Sr. Vice President, Head of Molecular Dx Sr. Vice President, Digital Insights Business Business Area Bus. Area Area Joined QIAGEN in 2004 as Vice President Corporate Joined QIAGEN
Slide 65: Executive Committee
Executive Committee Stephany Foster Barthold Piening Sr. Vice President, Head of HR Sr. Vice President, Head of Global Operations Joined QIAGEN in 2005 as Head of Global Internal Audit and Joined QIAGEN in December 2018 as Senior Vice President, was most recently Vice President, Head of Human Head o
Slide 66: Supervisory Board
Supervisory Board Lawrence A. Rosen Dr. Metin Colpan Chair of the Supervisory Board Supervisory Director Joined the Supervisory Board in 2013 and was appointed He is a co-founder of QIAGEN, its first Chief Executive Chair in 2020. He is Chair of the Audit Committee and Chair Officer and a Managing D
Slide 67: Supervisory Board
Supervisory Board Thomas Ebeling Dr. Toralf Haag Prof. Dr. Ross L. Levine Supervisory Director Supervisory Director Supervisory Director Joined the Supervisory Board in February 2021. Mr. Ebeling Dr. Toralf Haag joined the Supervisory Board and the Audit Joined the Supervisory Board and its Science
Slide 68: Supervisory Board
Supervisory Board Prof. Dr. Elaine Mardis Elisabeth E. Tallett Supervisory Director Supervisory Director Joined the Supervisory Board in 2014. She is a member of Joined the Supervisory Board, as well as the Audit the Science and Technology Committee and the Committee and Compensation Committee, in 2
Slide 69: Scientific Advisory Board
Scientific Advisory Board Chair Members Dr. Peter Kaspar Dr. Neville Sanjana Prof. Dr. Ross Core Faculty Member at the New Levine Leadership positions at Roche Diagnostics and bioMérieux during York Genome Center and career in diagnostics, Life Sciences and Assistant Professor at New York pharmaceut
Slide 70: Financial information
Financial information Sample to Insight
Slide 71: Disciplined capital allocation strategy to support business growth while increasing returns
Disciplined capital allocation strategy to support business growth while increasing returns Business reinvestments Fuel sustainable and profitable growth, especially in the five pillars Capital allocation strategy Value-enhancing M&A Ongoing disciplined review of bolt-on deals Share repurchase progr
Slide 72: Maintaining financial flexibility with appropriate leverage and cost-efficient debt structures
Maintaining financial flexibility with appropriate leverage and cost-efficient debt structures Structure as of December 31, 2020 Leverage ratio (Net debt / EBITDA) $2.1 billion $715 billion 1.3 1.6 1.5 1.4 1.6 1.5 1.1 1.2 1.1 0.9 Cash and short-term Convertible investments Bonds 2021 2012 2013 2014
Slide 73: Q3 2021 results
Q3 2021 results Sample to Insight
Slide 74: Q3 2021: Summary
Q3 2021: Summary 1 2 High-performing Strengthening portfolio Strong cash flow Upgraded 2021 outlook base business Reflects strong Q3 results Five pillars of growth Dynamic 198% rise in free +17% CER growth in performing well and setting cash flow while investing in Net sales: ≥ +15% CER non-COVID pr
Slide 75: Q3 2021: Ongoing solid trends in non-COVID product group sales growth
Q3 2021: Ongoing solid trends in non-COVID product group sales growth Net sales exceeded outlook +10% CER vs. Q3 2020 +17% CER in non-COVID product groups Adj. EPS exceeded outlook $0.58 CER vs. $0.52-0.53 CER FY 2021 outlook upgraded Healthy cash flow Strengthening foundation for future growth • Op
Slide 76: Q3 2021: All product groups delivering growth in non-COVID areas
Q3 2021: All product groups delivering growth in non-COVID areas Sales by product group Q3 2021 sales (In $ millions at actual rates) ■ Sample technologies +10% CER • Mid-single digit CER growth in non-COVID group sales vs. decline in COVID-19 product group sales $571 $567 $567 • Strong QIAprep&
Slide 77: Q3 2021: Growth in all regions as non-COVID sales gain momentum
Q3 2021: Growth in all regions as non-COVID sales gain momentum Americas • Dynamic QuantiFERON sales growth of >50% CER • +19% CER growth in the U.S. Europe / Middle East / Africa • Ongoing demand for COVID testing solutions • UK, Italy, Belgium and Switzerland all grew at double-digit CER rates Ame
Slide 78: Q3 2021: Five pillars update – investing to drive sustainable post-pandemic expansion
Q3 2021: Five pillars update – investing to drive sustainable post-pandemic expansion Sample QIAcuity QuantiFERON NeuMoDx QIAstat-Dx technologies digital PCR • PAXgene Saliva • QIAreach-QFT TB • New COVID-19 • U.S. government • Respiratory 4-plex Collector launched launched as modern wastewater test
Slide 79: Q3 2021: New Diagnostic solutions set for launch to address key market opportunities
Q3 2021: New Diagnostic solutions set for launch to address key market opportunities QIAstat-Dx Respiratory 4-plex panel CE-IVD QIAreach QuantiFERON-TB Increased use of multiplex panels for respiratory illness diagnosis Unique capabilities for high-disease burden, low-resource areas % of all respira
Slide 80: Q3 2021: Investing in business expansion while returning value to shareholders
Q3 2021: Investing in business expansion while returning value to shareholders Adjusted EPS Adj. operating Operating Cash Targeted investments into five pillars of growth income Flow Manufacturing scale-up and test menu expansion for QIAstat-Dx and NeuMoDx (In $ per share) (In $ millions) (In $ mill
Slide 81: Outlook: Full-year 2021 outlook updated to reflect stronger than expected Q3 results
Outlook: Full-year 2021 outlook updated to reflect stronger than expected Q3 results FY 2021 outlook FY 2021 outlook Q4 2021 outlook Updated Previous (July 2021) Net sales ~ -9% CER ≥ +15% CER ≥ +12% CER Anticipated currency impact Up to -1 p.p ~ + 2 p.p. ~ + 2-3 p.p. Adjusted EPS ≥ $0.60 CER ≥ $2.4
Slide 82: Appendix
Appendix Sample to Insight
Slide 83: Q4 and FY 2021: Outlook and assumptions
Q4 and FY 2021: Outlook and assumptions (As of November 3, 2021) Q4 2021 outlook FY 2021 outlook ~ -9% CER ≥ +15% CER Net sales (Prior year: $571.2 m) (Prior year: $1,870.3 m) Anticipated currency impact(1) Up to -1 p.p. ~ +2 p.p. > $0.60 CER ≥ $2.48 CER Adjusted EPS(2) (Prior year: $0.68) (Prior ye
Slide 84: Q3: Consolidated Statements of Income (unaudited)
Q3: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) September 30, 2021 September 30, 2020 Net sales 534,745 483,763 Cost of sales: Cost of sales 181,214 147,297 Acquisition-related intangible amortization 16,314 15,692 Total cos
Slide 85: 9M: Consolidated Statements of Income (unaudited)
9M: Consolidated Statements of Income (unaudited) Nine months ended Nine months ended (In $ thousands, except share data) September 30, 2021 September 30, 2020 Net sales 1,669,259 1,299,112 Cost of sales: Cost of sales 540,576 394,084 Acquisition-related intangible amortization 51,687 45,746 Total c
Slide 86: 2021: Quarterly sales by product group
2021: Quarterly sales by product group Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 227 47% 42% 203 1% -3% 202 -5% -6% 632 11% 8% Diagnostic solutio
Slide 87: 2020: Quarterly sales by product group
2020: Quarterly sales by product group Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 154 22% 24% 200 46% 49% 214 57% 56% 236 59% 55% 804 47% 47% Diag
Slide 88: 2021: Sales by non-COVID and COVID-19 product groups
2021: Sales by non-COVID and COVID-19 product groups Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 364 20% 16% 408 57% 52% 376 18% 17% 1,148 30%
Slide 89: 2020: Sales by non-COVID and COVID-19 product groups
2020: Sales by non-COVID and COVID-19 product groups Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 303 -5% -4% 259 -25% -23% 320 -8% -8% 371 0%
Slide 90: 2021: Quarterly sales by product type, customer class and region
2021: Quarterly sales by product type, customer class and region (In $ millions at actual rates / change in actual, CER rates) Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 Product type Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Consumables and related revenues 498 53% 48%
Slide 91: 2020: Quarterly sales by product type, customer class and region
2020: Quarterly sales by product type, customer class and region (In $ millions at actual rates / change in actual, CER rates) Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 Product type Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Consumables and related revenues 326 4% 6% 37
Slide 92: Q3 and 9M 2021: Reconciliation adjusted results (unaudited)
Q3 and 9M 2021: Reconciliation adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted Third quarter 2021 sales profit income income tax rate income EPS Reported results 534.7 337.2 131.9 151.5 (18.3) 12% 133.1 0.57 Adjustments Business integration,
Slide 93: Q3 and 9M 2021: Footnotes for reconciliation adjusted results (unaudited)
Q3 and 9M 2021: Footnotes for reconciliation adjusted results (unaudited) (a) Results for 2021 include integration-related activities for the NeuMoDx acquisition in September 2020. Results for 2020 include expenses associated with the public takeover offer for QIAGEN. A restructuring program was ini
Slide 94: 2021: Quarterly income statement summary
2021: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 Net sales 567.2 567.3 534.7 1,669.3 Net sales (CER) 549.5 547.7 530.8 1,628.0 Gross profit 370.6 369.2 337.2 1,077.0 Gross profit margin 65.3% 65.1% 63.1% 6
Slide 95: 2020: Quarterly and full-year income statement summary
2020: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 Net sales 372.1 443.3 483.8 571.2 1,870.3 Gross profit 243.5 295.0 320.8 373.4 1,232.7 Gross profit margin 65.5% 66.5% 66.3% 65.4% 65.9% Adjus
Slide 96: Consolidated Balance Sheets
Consolidated Balance Sheets September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2021 2020 (In $ thousands, except par value) 2021 2020 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 617,541 597,984 Current portion of long-term deb
Slide 97: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Nine months ended Nine months ended September 30, September 30, September 30, September 30, (In $ thousands) 2021 2020 (In $ thousands) 2021 2020 Cash flows from operating activities: Cash flows from financing activities: Net income 383,413 146,503 R
Slide 98: Q3 and 9M 2021: Currency impact
Q3 and 9M 2021: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2021 U.S. dollar 270.7 270.7 51% 0.0 Euro 110.6 109.8 21% -0.8 British pound 24.0 22.5 4% -1.5 Japanese yen 16.1 16.7 3% 0.6 Other currencies 113.3 111.1
Slide 99: Employees as of September 30, 2021
Employees as of September 30, 2021 Europe / Asia Pacific / Total Total Americas Middle East / Africa Japan / ROW Q3 2021 Q3 2020 Change Production 445 1,220 154 1,819 1,329 37% R&D 221 734 48 1,003 893 12% Sales 580 870 808 2,258 2,173 4% Marketing 81 184 85 350 319 10% Administration 80 388 158 626
Slide 100: Your contacts
Your contacts John Gilardi Vice President Corporate Communications and IR Calendar Phone: +49 2103 29 11711 Q4 2021 results February 2022 Mobile: +49 152 018 11711 E-mail: john.gilardi@qiagen.com Q1 2022 results April 2022 Annual General Meeting June 2022 Phoebe Loh Senior Director Share information